# Nuclide record prostate-cancer-signalling (pathway). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/pathways/prostate-cancer-signalling/>
  a schema:BioChemEntity ;
  nuclide:kind "pathway" ;
  schema:identifier "prostate-cancer-signalling" ;
  schema:name "Prostate cancer (KEGG map)"@en ;
  schema:alternateName "KEGG hsa05215"@en, "Prostate cancer"@en ;
  schema:description "KEGG's prostate cancer map centres on the androgen receptor, the hormone switch that prostate cells depend on, plus loss of PTEN and NKX3.1 that lets PI3K/AKT growth signalling run free. Hormone therapy, AR antagonists and now AKT inhibitors act on these two arms."@en ;
  schema:url <https://nuclide.cc/pathways/prostate-cancer-signalling/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.kegg.jp/pathway/hsa05215>, <https://doi.org/10.1038/nrc4016> ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/> ;
  nuclide:targets <https://nuclide.cc/targets/psma/> ;
  nuclide:drugs <https://nuclide.cc/drugs/enzalutamide/>, <https://nuclide.cc/drugs/abiraterone/>, <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/drugs/olaparib/> ;
  nuclide:pathways <https://nuclide.cc/pathways/lineage-plasticity-neuroendocrine/> .